A Natural Small Molecule Harmine Inhibits Angiogenesis and Suppresses Tumour Growth through Activation of p53 in Endothelial Cells by Dai, Fujun et al.
A Natural Small Molecule Harmine Inhibits Angiogenesis
and Suppresses Tumour Growth through Activation of
p53 in Endothelial Cells
Fujun Dai1, Yihua Chen1*, Yajuan Song1, Li Huang1, Dong Zhai1, Yanmin Dong1, Li Lai1, Tao Zhang1,
Dali Li1, Xiufeng Pang1, Mingyao Liu1,2*, Zhengfang Yi1*
1 Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China, 2Center for
Cancer and Stem Cell Biology, Institute of Biosciences and Technology and Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center,
Houston, Texas, United States of America
Abstract
Activation of p53 effectively inhibits tumor angiogenesis that is necessary for tumor growth and metastasis. Reactivation of
the p53 by small molecules has emerged as a promising new strategy for cancer therapy. Several classes of small-molecules
that activate the p53 pathway have been discovered using various approaches. Here, we identified harmine (b-carboline
alkaloid) as a novel activator of p53 signaling involved in inhibition of angiogenesis and tumor growth. Harmine induced
p53 phosphorylation and disrupted the p53-MDM2 interaction. Harmine also prevented p53 degradation in the presence of
cycloheximide and activated nuclear accumulation of p53 followed by increasing its transcriptional activity in endothelial
cells. Moreover, harmine not only induced endothelial cell cycle arrest and apoptosis, but also suppressed endothelial cell
migration and tube formation as well as induction of neovascularity in a mouse corneal micropocket assay. Finally, harmine
inhibited tumor growth by reducing tumor angiogenesis, as demonstrated by a xenograft tumor model. Our results
suggested a novel mechanism and bioactivity of harmine, which inhibited tumor growth by activating the p53 signaling
pathway and blocking angiogenesis in endothelial cells.
Citation: Dai F, Chen Y, Song Y, Huang L, Zhai D, et al. (2012) A Natural Small Molecule Harmine Inhibits Angiogenesis and Suppresses Tumour Growth through
Activation of p53 in Endothelial Cells. PLoS ONE 7(12): e52162. doi:10.1371/journal.pone.0052162
Editor: Carl G. Maki, Rush University Medical Center, United States of America
Received May 10, 2012; Accepted November 14, 2012; Published December 27, 2012
Copyright:  2012 Dai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was partially sponsored by the Major State Basic Research Development Program of China (2012CB910400) (http://www.most.gov.cn),
(2009CB918402) (http://www.973.gov.cn), National Natural Science Foundation of China (30930055, 30971523 and 81071807) (http://www.nsfc.gov.cn) and the
Science and Technology Commission of Shanghai Municipality (11DZ2260300) (http://www.stcsm.gov.cn). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yizhengfang@gmail.com (ZY); ibms.ecnu@gmail.com (ML); yhchen79@gmail.com (YC)
Introduction
The tumor suppressor p53 plays a key role in the regulation of
cell cycle, apoptosis, DNA repair, and senescence [1] in response
to diverse stress stimuli, including DNA damage, oncogene
activation and hypoxia [2]. p53 acts as a transcriptional factor
and activates various genes to exert specific functions involved in
tumor development. Murine double minute 2 (MDM2), the main
regulator of p53, inhibits the function of p53 through direct
interaction [3].
In addition to the direct effect of targeting tumor cells, there are
accumulating evidences that show activation of p53 may also
effectively inhibit angiogenesis, which is one of the most important
hallmarks in the cancer development [4], and is critical for tumor
growth and metastasis [5]. Overexpression of p53 inhibits
angiogenesis by up-regulation of its downstream target genes such
as thrombospondin 1 (TSP-1) [6] and brain-specific angiogenesis
inhibitor 1 (Bai1) [7]. Therefore, the p53 activation is also
fundamentally involved in angiogenic processes [5].
Because of the high potential of p53 to elicit apoptosis or
growth arrest in cells, pharmacological reactivation of the p53
tumor suppressor is a promising strategy for anti-cancer therapy
[8]. Recently, proposed model suggested that p53 activation
in vivo includes three major steps: (1) p53 stabilization, (2) release
from MDM2 (i.e. antirepression) [9], and (3) promoter-specific
activation [10]. Previous reports showed that some small
compounds induces cancer cell cycle arrest and apoptosis
through restoration of p53 pathway [2,11] and some other small
molecules such as Inauhzin were identified that induced the level
and activity of p53 consequently and effectively repressed the
growth of xenograft tumours [12]. Indeed, several p53-reactivat-
ing compounds are currently being tested in clinical trials,
including mutant p53-reactivating PRIMA-1 analog APR-246
[8].
Harmine, a small-molecule b-carboline alkaloid, is a naturally
occurring compound in some plant species [13]. Previous research
has shown that harmine plays some roles in anti-cancer treatments
[14], as well as possesses anti-leishmanial properties [15] and an
anti-viral effect [16] via multiple signaling pathways such as kinase
[17] and mitochondrial signaling pathways [18]. However, there
are no evidences that show harmine or its analogues exert their
bioactivities via the p53 signaling pathway.
In the present study, we identified harmine as a novel activator
of the p53 pathway and characterized its anti-angiogenic and anti-
tumor effects via p53 signaling pathway in endothelial cells.
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e52162
Materials and Methods
Cell Lines, Animals and Regents
Human umbilical vein endothelial cells (HUVECs) were
purchased from Sciencell Research Laboratories (Beijing, China).
Human A549 lung cancer cells provided by ATCC were cultured
in RPMI 1640 medium. Mice were obtained from National
Rodent Laboratory Animal Resources (Shanghai, China). All
animal procedures were approved by the institutional Animal
Ethics Committee of East China Normal University. Vascular
endothelial growth factor (VEGF) and growth factor-reduced
Matrigel were purchased from R&D Biosciences (San Diego, CA).
p53-siRNA and negative control oligonucleotides were purchased
from GenePharma (Shanghai, China). Harmine ($98% purity)
was obtained from Sigma-Aldrich).
Western Blotting and Co-immunoprecipitation
Harvested cells were lysed in RIPA buffer containing protease/
phosphatase inhibitors (Roche). Lysates were combined with
sample loading buffer and heated at 100uC. Cytoplasmic and
nuclear extractions were performed. For the co-immunoprecipi-
tation assay, whole cell lysates or fractionated samples were
incubated with specific antibodies overnight for precipitation and
then incubated with protein A/G-Sepharose beads (GE Health-
care Bio-Sciences). Protein samples were eluted in sample buffer
and subjected to SDS-polyacrylamide gel electrophoresis. Anti-
bodies used were as follows: anti-p53, anti-MDM2 and anti-TSP1
purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and
anti-b actin, anti-phospho-p53 (ser-37), anti-phospho-p53 (ser-20),
anti-phospho-p53 (ser-15), anti-p21, anti-cyclin B1, anti-cyclin E,
anti-cyclin D1, anti-cyclin A, anti-CDC2, anti-CDK2, anti-Poly
(ADP-ribose) polymerase (PARP), anti-Bcl2 and anti-survivin
purchased from Cell Signaling Technology (Boston, MA).
Antibody of anti-cH2AX was from Abcam Inc. (Cambrige, MA).
ProteOn XPR36 Protein Interaction Array
Measurement of binding affinities between harmine and
MDM2 was performed as described elsewhere [19] with some
modification. Briefly, a GLH chip was used in this assay.
glutathione S-transferase (GST) and GST-MDM2 were dissolved
in 10 mM NaAc and immobilized onto separate erect channels of
the sensor chip by general amine coupling. MDM2-GST was
immobilized to around 17400 RUs. After baselines were stable,
harmine was dissolved in PBS-T buffer flowing through the chip
horizontally. Data were analyzed with ProteOn managerTM
software using the Langmuir model (A+B « AB) for kinetic data
fitting.
Immunofluorescence Staining
As described in a previous report [20], Harmine-treated
HUVECs were fixed using 4% formaldehyde and washed with
phosphate buffered saline (PBS). Fixed cells were treated with
0.2% Triton-X 100. After blocking in 0.5% bovine serum
albumin, cells were incubated with the primary antibody at room
temperature, followed by incubation with the secondary antibody.
Then, 49,6-diamidino-2-phenylindole (DAPI) was added to
samples, followed by incubation while protected from light.
Images were recorded by confocal microscopy (Leica).
Real-Time RT-PCR
Total RNA was extracted from cells using Trizol reagent, and
then cDNA was synthesized. Real-time PCR was performed using
MxPro-Mx3005P software and a STRATAGENE Real-Time
PCR instrument. Primers used were as follows: Bai1, forward 59-
ACTCATCCTGCGACGGTGTG-39 and reverse 59-
TCCCTCAGGT CCTTCATGCG-39; p21, forward 59-CTC
TCAGGGTCGAAAACGG-39 and reverse 59-GATGTA-
GAGCGGGCCTTT G-39; survivin, forward 59-
GCGCTTTCCT TTCTGTCAAG-39 and reverse 59-TAAGA
CATTGCTAAGGGGCC-39; TSP-1, forward 59-
TATGCTGGTGGTAGACTAGG-39 and reverse 59-TCTAG-
GAG TCCACACTGATG-39; CDC2, forward 59-CTAG-
CATCCCATGTCAAAAAC-39 and reverse 59-ACGAAGTA-
CAGCTGAA GTTTG-39; CDK2, forward 59-GCCAGGA
GTTACTTCTATGC-39 and reverse 59-GTCACATCCTG-
GAAG AAAGG-39; cylinB1, forward 59-GACTGTCAAGAA-
CAAGTATGC-39 and reverse 59-CAGTAGGAA GTAACCA-
CATTC-39; P53, forward 59-TGTTCCGAGAGCTGAATGAG-
39 and reverse 59-GCAAGCAAGGGTTCAAAGAC-39. Expres-
sion levels of genes were relative to expression of the housekeeping
gene b-actin.
Cell cycle, Apoptosis and Proliferation Analyses
For cell cycle analysis, cells were harvested and washed with
PBS. Then, collected cells were re-suspended in 70% cold ethanol
and fixed overnight at 4uC. After centrifugation, cells were re-
suspended with PBS containing RNase and incubated at 37uC for
30 minutes. Cells were then stained with PI and analyzed by flow
cytometry. Hamine-induced apoptosis of HUVECs or HUVECs
transfected with p53 siRNA was determined was quantified by an
annexin V-FITC/PI dual staining assay. Briefly, cells were
collected, centrifuged and re-suspended with PBS. After centrifu-
gation, cells were re-suspended with binding buffer and incubated
with annexin V and PI. Analysis was performed by flow cytometry.
The effect of harmine on the proliferation of HUVECs was
assessed by an MTS assay according to methods described
elsewhere [21]. HUVECs or human A549 lung cancer cells were
seeded in 96-well plates (5000 cells/well). After culture for 12
hours, cells were treated with various concentrations of harmine
for 48 hours. Then, an AQueous One solution (Promega,
Madison, WI) was added, and absorbances were measured with
a microplate reader (SpectraMax 190; Molecular Devices).
P53 Silencing Using p53 siRNA
HUVECs were seeded in 6-well plate and transfected with p53
siRNA the next day. The effect of siRNA for p53 silencing was
examined by Real-Time RT-PCR and western blot after the
transfection for 36 hours and 72 hours respectively. After
transfection for 16 hours, cells were treated with various
concentrations of harmine for 48 hours.
Comet Assay
Alkaline comet assays were performed according to the previous
study [22] with some modifications. In brief, HUVECs were
treated with various concentrations of harmine for 48 hours, and
then harvested. About 5 6 104 cells treated with harmine or
untreated in 40 ml of phosphate-buffered saline mixed with an
equal amount (40 ml) of 1% lower melting agarose were pipetted
onto the slides that were covered with 100 ml of 0.5% normal
molten agarose at 60uC. The cell suspension spread using
a coverslip, and the slides were maintained at 4uC for 15 min to
allow the gel to solidify. After removal of the coverslip, the slides
were immersed in freshly prepared cold lysis solution (2.5 M NaCl,
100 mM Na2EDTA, 10 mM Tris, pH 10.0, 1% sodium sarcosi-
nate) with 1% Triton X-100 at 4uC for 1 hour. Electrophoresis
was carried out in a horizontal gel electrophoresis tank filled with
fresh electrophoresis solution (1 mM Na2EDTA, 300 mM NaOH,
pH 13.0) for 20 min (300 mA at 10 V) 4uC. Slides were rinsed
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twice in Tris buffer (0.4 M Tris, pH 7.5) for 15 min (neutralizing
the excess alkali) and stained with 75ml of propidium iodide (5 mg/
ml) for 30 min. The slides were then examined using a Leica
fluorescence microscope under6 200 magnification.
Cell Migration and Tube Formation Assays
HUVECs were cultured in 6 well plates precoated with 1%
gelatin (Sigma-Aldrich) and grown to confluency. After the
treatment of mitomycin C for 2 hours, the cells were scratched
with a pipette tip followed by the addition of harmine. Images of
wound area were recorded after 8 hours, and the number of
migrated cells was counted. Another migration test of HUVECs
was assessed by a modified transwell assay as described elsewhere
[23]. As for 549 lung cancer cells migration assay, cells were
seeded in 6 well plates and grown to confluency. After the
starvation overnight, the following steps were described as above.
After the treatment for 12 hours, the number of migrated cells was
counted. During the migration assays, we did not find the
phenomenon of apoptosis. For the tube formation assay, 26104
cells per well were seeded in pre-cooled 96 well plates coated with
Matrigel [24] and containing medium with or without harmine,
followed by incubation at 37uC with 5% CO2. After 12 hours,
tube structures in eight randomly chosen fields were photographed
and counted by scoring the enclosed networks.
Ex vivo and In vivo Angiogenesis Assays
A rat aortic ring assay was performed as described elsewhere
[25] with some modification. Briefly, thoracic aortas were sliced
into rings of 1–1.5 mm in circumference. VEGF (200 ng) with or
without harmine in serum-free MCDB131 medium was added to
aortic rings coated with Matrigel. Medium was exchanged every 2
days. On day 7, microvessel outgrowths were photographed and
analyzed. A mouse corneal micropocket assay was performed as
described elsewhere [26] with some modification. Briefly, slow-
release pellets (0.3560.35 mm) containing 200 ng VEGF with or
without 5 mg harmine were prepared with a sucrose octasulfate-
aluminum complex and poly-HEMA. A corneal micropocket was
created in the eye of a 4-5-week-old C57BL/6 mouse with
a modified needle, and pellets were implanted into these
micropockets. Chlortetracycline hydrochloride ophthalmic oint-
ment was applied to each operated eye to prevent infection. After
7 days, the vessel length and clock hours of new blood vessels were
examined under a stereomicroscope and recorded. The area of
neovasculature was calculated according to the formula: Area
(mm2) = 0.2 6 p 6 VL (mm) 6 CN (mm), where VL is the
maximal vessel length extended from the limbal vasculature
toward the pellet and CN is the clock hours of neovascularization,
1 clock hour equals 30 degrees of arc.
Tumor Xenograft Model and Immunohistochemistry
Five-week-old nude mice were allowed to acclimate for a week
before inoculation with A549 cancer cells. Cells (26106) prepared
in PBS were injected subcutaneously. After the tumor grew to 50–
100 mm3, mice were intralesionally injected with harmine
(30 mg/kg) every day for 21 days. An equivalent volume of
DMSO was injected as a control. Measurements of body weight
and tumor dimensions were performed daily. The tumor volume
was considered the volume equal to 0.526AB2, where A is the
long axis and B is the short axis.
As described elsewhere [27], solid tumors were removed from
sacrificed mice and fixed with 10% formaldehyde. Paraffin-
embedded tissues were sectioned at 4 mm and then stained using
a Blood Vessel Staining Kit (Millipore). The optical density of
stained blood vessels was analyzed by Image-Pro Plus software,
according to the following formula: Mean integrated optical
density (IOD) = IOD/area of the tumor section.
Statistical Analysis
Results were statistically analyzed using the Students t-test with
Microsoft Excel. Some statistical analyses were performed using
two-way analysis of variance followed by the Bonferroni post-hoc
test using the GraphPad Quickcalc online web site. All experi-
ments were repeated at least three times. A value of P,0.05 was
considered significant.
Results
Harmine Activates p53 by Inducing Phosphorylation of
p53 and Binding to MDM2
A number of reports show that inhibiting the MDM2-p53
interaction can be potentially important for activation of p53 and
cancer therapy [3]. We first tested the effect of harmine on the
p53-MDM2 interaction in HUVECs using a co-immunoprecip-
itation assay with anti-p53 and anti-MDM2 antibodies. Our data
showed that the amount of MDM2 associated with p53 was
dramatically decreased with increasing concentrations of harmine,
although endogenous p53 was increased with the addition of
harmine (Figure 1B), suggesting that harmine inhibited the
endogenous interaction of p53 with MDM2 in a dose-dependent
manner.
In the p53 signaling pathway, modifications of p53 phosphor-
ylation at various sites, such as serines 15, 20, and 37, are involved
in regulation of p53 functions. p53 phosphorylation deters the
association between p53 and MDM2 and prevents p53 ubiquiti-
nization that degrades p53 [28]. To understand the effect of
harmine on p53 phosphorylation, we examined three serines sites
of p53 by western blot. As shown in Figure 1C and Figure 1D,
harmine significantly induced p53 phosphorylation at ser-37 and
ser-15 sites in a dose-dependent manner, but had little effect on
p53 phosphorylation at ser-20 in endothelial cells. Phosphorylation
of p53 occurs in response to some stimulies such as DNA damage.
To test the phosphorylation of p53 induced by harmine due to
DNA damage, we used cH2AX as a marker for DNA damage and
performed comet assay. As shown in Figure S1, harmine did not
induce DNA damage obviously. These data suggested that
harmine induced p53 phosphorylation maybe not because of
DNA damage.
On the other hand, The p53-MDM2 interaction is a pivotal
event involved in tumor progression [29], and targeting the
MDM2-p53 interaction by small molecules to reactivate p53 has
emerged as a promising new strategy for cancer therapy [30]. To
determine whether harmine bound to MDM2, we examined the
interaction of harmine with MDM2 using a ProteOn XPR36
Protein Interaction Array. Quantitative analysis of the binding
data under the deduction of GST showed that harmine rapidly
bound to MDM2 protein with a KD of 48 mM in an association
phase of 70 seconds (Figure 1E and Table 1). Binding of harmine
to MDM2 was characterized by a very fast association and
dissociation (Figure 1E). This result was fitted by the simplest 1:1
interaction model (Langmuir model).
Harmine Induces p53 Stabilization and Nuclear
Accumulation
As a negatively regulator of p53, MDM2 promotes p53
degradation [31]. On the other hand, interaction with MDM2
protein also prevents p53 from degradation and promotes p53
stabilization [32]. Therefore, we examined whether expression
levels of p53 and MDM2 were affected in harmine-treated cells.
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Results showed that harmine upregulated p53 protein expression
in a dose-dependent manner, but had little effect on the protein
expression of MDM2 (Fig. 2A). Next, we examined the
stabilization of p53 induced by harmine. As shown in Figure 2B,
in the absence of harmine and in the presence of cycloheximide
(CHX), which inhibits protein synthesis, the protein level of p53
was lower in cells treated with CHX for 8 hours, compared with
that in untreated endothelial cells, indicating p53 degradation
during inhibition of protein synthesis. Conversely, in the presence
of CHX, the protein level of p53 did not significantly change in
harmine-treated endothelial cells. These results suggested that
harmine prevented p53 degradation and induced stabilization of
p53 in endothelial cells.
A previous report showed that interruption of the p53-MDM2
interaction and p53 phosphorylation results in nuclear accumu-
lation of p53 [33]. To investigate nuclear accumulation of p53
induced by harmine, we examined the expression level of p53 in
the nucleus and cytoplasm by western blot using an anti-p53
antibody. As shown in Figure 2C, nuclear levels of p53 were
elevated significantly in cells exposed to harmine (left panel), while
cytoplasmic levels of p53 hardly changed with the addition of
harmine (right panel). To confirm nuclear accumulation of p53
induced by harmine, we examined the expression level of p53 in
the nucleus by immunofluorescence staining using the anti-p53
antibody. Our data indicated that harmine increased nuclear
localization of p53 in a dose-dependent manner (Figure 2D).
These results suggested that p53 stabilization resulted from
inhibition of the p53-MDM2 interaction, and p53 phosphoryla-
tion induced by harmine was an important factor for nuclear
accumulation in endothelial cells.
Harmine Induces p53 Transcriptional Activity
When the p53-MDM2 interaction is disrupted and the protein
level of p53 in the nucleus is increased, transcriptional activity of
p53 is activated. To further investigate the effect of harmine on the
p53-MDM2 signaling pathway, we examined the expression levels
of p53-target genes such as p21, survivin, CDC2, cyclin B1 and CDK2.
As shown in Figure 3A, left panel, harmine increased the mRNA
level of p21, and inhibited the expression of survivin, CDC2, cyclin B1
and CDK2 in a dose-dependent manner, suggesting that harmine
increased p53 nuclear accumulation and activated its transcrip-
tional activity in endothelial cells. Accordingly, harmine inhibited
the expression levels of both cyclin B1 and CDC2, which are
critical regulators of the G2/M checkpoint [34]. Furthermore,
harmine inhibited the expression levels of cyclin A and CDK2, but
did not affect the expression of cyclin E and cyclin D1.
To understand the molecular mechanism of harmine in
endothelial cells, which are very important in angiogenesis, we
examined the expression of downstream p53-target genes, TSP-1
[6] and brain angiogenesis inhibitor 1 (Bai1) [7], which are both
endogenous angiogenesis inhibitors. As shown in Figure 3B,
harmine increased the mRNA level of TSP-1 and Bai1 in a dose-
dependent manner in HUVECs and upregulated the expression of
TSP-1 protein. These results suggested that harmine activated
transcriptional activity of p53, resulting in changes of p53-target
gene expression.
Harmine Induces Apoptosis and Cell Cycle Arrest in
HUVECs
As a cellular gatekeeper, activation of p53 induces cell growth
arrest and apoptosis [35]. To identify the function of harmine in
apoptosis, we performed a cell apoptosis assay using annexin V/PI
staining. As shown in Figure 4A, left panel, 20 mM harmine
increased HUVEC apoptosis (15.45%) by 3-fold compared with
that in untreated cells (5.34%). Harmine-induced HUVEC
apoptosis was further confirmed by cleavage of poly (ADP-ribose)
polymerase (PARP), a marker of apoptosis (Figure 4A, right panel)
[36], and by the decrease of anti-apoptotic proteins Bcl-2 [37] and
survivin [38] in endothelial cells (Figure 4A, right panel).
To further identify whether harmine induced apoptosis in p53-
depemdent manner, we tried to silence the p53 gene with siRNA
targeting p53 mRNA in HUVECs. As shown in Figure S2, 20 mM
harmine did not significantly increased HUVEC apoptosis
(13.42%) compared with that in untreated cells (11.08%). These
results suggested that harmine-induced apoptosis may depend on
p53 pathway in HUVECs.
We further examined the effect of harmine on the cell cycle
progression of endothelial cells. In the presence of harmine, cells
were visibly arrested in G2/M, accompanied by a increased G2/
M phase of the cell cycle (Figure 4B and Table 2). To evaluate the
effect of harmine on HUVEC proliferation, we performed a cell
proliferation assay. Harmine treatment of HUVECs resulted in
inhibition of HUVEC proliferation as indicated by a decrease of
absorbance at 490 nm, comparing with that of the control
(Figure 4C).
Harmine Inhibits HUVEC Migration and Tube Formation
To evaluate the effect of harmine on the migration of HUVECs,
we performed wound healing and transwell migration assays.
Quantitative analysis by counting the number of migrated cells
showed that harmine inhibited cell migration in a dose-dependent
manner (Figure 5A and 5B). Endothelial cells are capable of
forming capillary-like structures in vitro, which mimics the process
of capillary formation in vivo. Harmine treatment inhibited the
ability of HUVECs to organize into capillary-like networks on
Matrigel in a dose-dependent manner (Figure 5C). These results
revealed that harmine inhibited neovascularization in vitro.
Harmine Inhibits Angiogenesis ex vivo and in vivo
To assess the anti-angiogenic activity of harmine, a rat thoracic
aorta ring assay was performed. As shown in Figure 6A, 50 mM
harmine obviously inhibited vessel sprouting from rat aortic rings.
Figure 1. Harmine activates p53 by inducing phosphorylation of p53 and binding to MDM2. (A) Chemical structure, molecular formula
and 212.25 molecular weight of harmine. (B) MDM2-p53 interaction assay of harmine-treated HUVECs. After harmine treatment for 48 hours, the
endogenous p53-MDM2 interaction was detected by a co-immunoprecipitation assay. (C) HUVECs were treated by harmine for 48 hours. The levels of
phosphorylation of p53 at ser-15, ser-20 and ser-37 were assessed by western blot. (D) Quantitative analysis of the phosphorylation level of p53 was
performed by Odyssey software. Harmine induced phosphorylation of p53 at ser-15 and ser-37, but not ser-20, in HUVECs. (E) Harmine bound to
MDM2 partly, as determined by a ProteOn XPR36 Protein Interaction Array.
doi:10.1371/journal.pone.0052162.g001
Table 1. The parameters of the binding of harmine to MDM2.
Parameter Rmax Rmax error KD KD error x
2
Units RU RU M M RU
MDM2 117.93 1.94 4.80E205 2.07E206 0.72
doi:10.1371/journal.pone.0052162.t001
Harmine Activates p53 Pathway
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e52162
The average area of sprouting vessels from thoracic aorta rings in
the harmine-treated group was only 30%, compared with that of
the control group. To further explore the effect of harmine on
angiogenesis in vivo, we performed a corneal angiogenesis assay,
Figure 2. Harmine suppresses the degradation of p53 and increases the accumulation of p53 in the nucleus. (A) Nuclear accumulation
of p53 protein and MDM2 expression in HUVECs after harmine treatment for 48 hours. (B) Harmine prevented the degradation of p53 in HUVECs in
the presence of CHX. (C) Harmine increased the nuclear levels of p53. Cells were treated with harmine for 48 hours, and then cytoplasmic and nuclear
extractions were performed to detect the levels of p53 protein in the cytoplasm and nucleus by western blot. (D) Nuclear accumulation of p53 in the
presence of various concentrations of harmine in HUVECs, as determined by immunofluorescence staining with an anti-p53 antibody. Cells were
stained with the anti-p53 antibody (red) and nuclei were counterstained with DAPI (blue).
doi:10.1371/journal.pone.0052162.g002
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which is an important animal model to evaluate angiogenesis. Our
data showed that 5 mg harmine significantly blocked neovascular-
ization (Figure 6B, arrows) induced by VEGF, as measured by the
vessel length, clock number and area of vessels in harmine-treated
eyes, compared with those of the control group (Figure 6C).
During experimentation, we did not observe symptoms of eye
inflammation including keratitis, corneal edema or advanced signs
of intraocular inflammation (data not shown). Results of these two
assays suggested that harmine inhibited angiogenesis ex vivo and
in vivo.
Harmine Suppresses Tumor Growth by Inhibiting Tumor
Angiogenesis
To determine the effects of harmine on tumor angiogenesis and
growth, we performed a xenograft lung tumor assay in nude mice.
After treatment for 21 days, 30 mg/kg harmine dramatically
inhibited the size (Figure 7A) and weight (Figure 7B, left panel) of
tumors, but there was no significant difference in body weight
between harmine-treated mice and control mice (Figure 7B, right
panel).
To ascertain whether inhibition of solid tumor growth resulted
from the decrease of new blood vessels, we examined vessel
formation in harmine-treated and control groups by immunohis-
tochemistry using antibodies against endothelial cell markers such
as vWF and CD31. Our data indicated that the microvessel
density of the harmine-treated group was much less than that of
the control group (Figure 7C), suggesting that harmine inhibited
lung tumor (A549 cells) growth in a xenograft mouse model by
inhibition of angiogenesis.
To further ascertain whether inhibition of angiogenesis is the
only reason for the suppression of tumor growth, we examined the
effect of harmine on the proliferation and migration of A549 lung
cancer cells. Our results showed that harmine also inhibited the
proliferation and migration of A549 lung cancer cells (Figure 7D
and 7E). These results suggested that harmine inhibited tumor
growth by both inhibition of angiogenesis and inhibition of cancer
cell proliferation.
Discussion
Our study as presented here identified non-peptidic carboline
harmine as a novel small molecule that possessed an ability to
induce p53 level and activity, consequently leading to p53
stabilization, nuclear accumulation and transcriptional activation
in endothelial cells. Moreover, harmine not only inhibited
angiogenesis in vitro and in vivo, but also suppressed tumor growth
by inhibiting tumor angiogenesis (Figure 8).
Figure 3. Harmine induces the expression of p53-target genes. (A) Protein expression levels of p21, cyclin B1, CDC2, cyclin A, CDK2, cyclin D1
and cyclin E in HUVECs treated by harmine for 48 hours. (B) Expression levels of endogenous angiogenesis inhibitors TSP-1 and Bai1 in HUVECs.
Protein expression level of TSP-1 was detected followed by addition of harmine for 48 hours, the mRNA levels of angiogenesis inhibitors were
detected after addition of harmine for 24 hours.
doi:10.1371/journal.pone.0052162.g003
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In p53 signaling pathway, p53 phosphorylation is one of the key
regulatory steps for activating p53 function. In different sites, p53
was phosphorylated by several kinases such as casein kinase II (CK
II), DNA-dependent protein kinase (DNA-PK), protein kinase C
(PKC) and mitogen-activated protein kinase (MAPK) [39]
followed by resulting in nuclear accumulation of p53 [33]. Other
study showed that, in response to DNA damage, phosphorylation
p53 at serines 15 and 37 by DNA-PK inhibited MDM2 binding to
p53 [40]. In addition, phosphorylation of p53 at serine 20 resulted
from some other kinases including PIK3 [41] is also thought to
play a role in modulating the negative regulation of p53 by
MDM2. In this study, we demonstrated that harmine induced p53
phosphorylation at ser-37 and ser-15 sites, but not the ser-20 site
(Figure 1C and 1D) followed by activating the p53 signals in
endothelial cells (Figure 1B). However, we did not find harmine
induced obvious DNA damage (Figure S1) measured by H2AX
and comet assays. These results, together with other studies,
suggested that harmine induces p53 phosphorylation possibly in
response to other factors and further studies in depth will be
conducted later.
Several studies have shown that the p53 activation reduces
nuclear export of p53, increased transcriptional activity of p53
Figure 4. Effects of Harmine on endothelial cell apoptosis, G2/M arrest and proliferation. (A) The proportion of apoptotic cells was
increased by harmine. Harmine induced cleavage of PARP and suppressed the expression of survivin and Bcl-2. The amount of cleaved PARP and the
expression levels of survivin and Bcl-2 in harmine-treated HUVECs were detected by western blot analysis with specific antibodies. (B) Cell cycle arrest
of HUVECs by various concentrations of harmine. Cells were treated with various concentrations of harmine for 48 hours, and then the cell cycle was
analyzed by flow cytometry. (C) Growth inhibition of HUVECs by harmine, as determined by an MTS assay. All of the experiments were performed
followed by addition of harmine for 48 hours. *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0052162.g004
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[42] and leads to growth arrest or apoptosis [43]. We found that
harmine induced p53 stabilization (Figure 2A and 2B) and nuclear
accumulation (Figure 2C and 2D). Furthermore, we also found
that harmine regulated the expression of downstream p53-target
genes, including cyclin B1, cyclin A and CDC2 (Figure 3A), which are
involved in the endothelial cell cycle. On the other hand,impor-
tantly, major roles of the p53 protein in cancer had also been
shown to limit angiogenesis by some mechanisms [5] including
directly increasing the production of endogenous angiogenesis
inhibitors and potential angiogenic markers such as Bai1 and TSP-
1 [44].
Our present study demonstrated that, in the dose-dependent
manner, harmine induced the expression of Bai1 and TSP-1
Table 2. Representation of the percentage in different
phases of the endothelial cell cycle distribution by harmine.
Har.(mM) Cell Cycle 0 10 20 50
Sub-G1 (%) 3.65 6.21 6.16 6.27
G1 phase (%) 71.20 63.78 50.03 28.48
S phase (%) 8.20 15.44 5.90 19.30
G2 phase (%) 15.27 12.07 34.21 39.00
Polyploid Population (%) 1.78 2.50 3.70 6.95
doi:10.1371/journal.pone.0052162.t002
Figure 5. Harmine inhibits HUVEC migration and tube formation. (A) Representative images and quantitative data of a wound healing
migration assay in the presence or absence of 20 mM harmine for 8 hours. (B) Results of transwell migration assays of HUVECs treated or untreated by
harmine for 8 hours. Right panel indicates quantitative data. (C) Representative images of tube formation assays of HUVECs in the presence or
absence of harmine (left panel) for 8 hours, and the quantitative data of tube formation assays (right panel). *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0052162.g005
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(Figure 3B). These results, together with the results shown in
Figure 1, suggested that harmine induced nuclear accumulation of
p53 and activated p53 transcriptional activities due to reactivation
of p53.
Angiogenesis is necessary of tumor growth. In this study, using
a xenograft mouse model and immunohistochemistry with anti-
vWF and anti-CD31 antibodies (Figure 7), we demonstrated that
harmine inhibited tumor growth with low side-effects by
suppressing tumor angiogenesis. A recent report [45] showed the
Figure 6. Harmine inhibits angiogenesis ex vivo and in vivo. (A) Representative images (left panel) and the optical density (right panel) of
microvessels sprouting from rat thoracic aorta rings in the absence or presence of harmine. The microvessel density of the untreated group was
considered as 100%. (B) Representative images of blood vessels in control eyes (left panel) and harmine-treated eyes (right panel). Black arrows
indicate blood vessels. (C) The vessel length, clock number and area of blood vessels in control and harmine-treated groups. At day 7, mice were
anesthetized, and images of blood vessels in control and harmine-treated eyes were recorded (n = 10). *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0052162.g006
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effect of harmine on angiogenesis in vitro and tumor-specific
capillary formation, but it did not demonstrate the anti-tumor
activity of harmine by suppressing tumor angiogenesis. In the
present study, we demonstrated that, under the effective dosage,
inhibiting tumor angiogenesis may be the important aspect of
antitumor activity of harmine and we expounded the novel roles of
harmine in anti-tumor activity by inhibiting angiogenesis.
Some other studies showed that p53 induced the activity of
PARP [46] and inhibited survival by activating p21, a regulator of
apoptosis and the cell cycle [47]. In addition,VEGF/VEGFR2
independent control of the anti-apoptotic pathway in endothelial
Figure 7. Harmine inhibits tumor growth and angiogenesis. (A) Inhibition of solid tumor growth in harmine-treated xenograft mouse models.
Images of solid tumors in control and experimental groups are shown. (B) The size of solid tumors was assessed in the absence or presence of
harmine, and statistical results of solid tumors and the body weight of mice. (C) The blood vessels of xenografted tumors in control and harmine-
treated groups. Blood vessels were stained using anti-vWF and anti-CD31 antibodies. Black arrows indicate positive blood vessels. (D) Growth
inhibition of A549 lung cancer cells treated by harmine for 48 hours, as determined by an MTS assay. (E) The quantitative data of A549 lung cancer
cells migration assays. A549 lung cancer cells were treated by harmine for 12 hours after the starvation overnight. *, P,0.05;**, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0052162.g007
Figure 8. Proposed model for the inhibition of angiogenesis and tumor growth by harmine. Harmine increases the activation of p53 and
induces the accumulation of stable p53 in the nucleus. Stable p53 down-regulates its downstream target genes, including CDC2, cyclin B1, survivin
and Bcl-2, leading to cell cycle arrest and apoptosis of HUVECs. In addition, p53 up-regulates the expression of TSP-1 and Bai1. All these events in
endothelial cells result in inhibition of tumor angiogenesis and growth.
doi:10.1371/journal.pone.0052162.g008
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cell is mediated by the activation of p53/caspases [48]. So, VEGF
and p53 expression are significantly correlated and might be
associated with relevant events involved in tumor biology [49]. In
this study, we demonstrated that harmine induced endothelial cell
apoptosis (Figure 4A), cell cycle arrest (Figure 4B) and reduced cell
viability (Figure 4C) mainly depending on p53 pathways.
Furthermore, harmine not only inhibited angiogenesis ex vivo in
an aorta ring assay (Figure 6A), which is consistent with a recent
report [45], but also inhibited VEGF-induced angiogenesis in vivo
in a mouse corneal assay (Figure 6B and 6C), the gold standard of
angiogenesis analysis [21]. All these results suggest that harmine
inhibits angiogenesis in vitro, ex vivo and in vivo.
In conclusion, our results not only indicate that harmine is
a novel activator of p53 in endothelial cells (Figure 8), but also
suggest that harmine may exert its biological activities on other
angiogenic diseases through p53 signaling pathway.
Supporting Information
Figure S1 Hrmine did not induce DNA damage. (A)
Immunofluorescent foci formation of cH2AX in HUVECs in the
presence or absence of harmine for 48 hours. (B) The quantitative
data of cH2AX foci in HUVECs treated by various concentrations
of harmine. At least 100 cells were measured per sample. (C)
HUVECs were treated by various concentrations of harmine for
48 hours, and then alkaline comet assay was performed. At least
500 cells were counted per sample.
(PPT)
Figure S2 Harmine did not have significant effect on
aopotosis of HUVEC transfected with p53 siRNA. (A) The
mRNA levels of p53 in HUVECs after the p53 siRNA interference
for 36 hours. HUVECs were transfected with p53 siRNA at the
concentration of 50 nM and 100 nM. The effect of these
concentrations was similar. (B) The expression of p53 protein
was detected by western blot in HUVECs transfected with p53
siRNA for 72 hours at the concentration of 50 nM and 100 nM
(left panel) and the quantitative data of p53 expression (right
panel). 100 nM p53 siRNA inhibited p53 expression (48.2%)
compared with the negative control. (C) The proportion of
apoptotic cells induced by harmine in HUVECs transfected with
p53 siRNA(100 nm). After the transfection for 16 hours, HUVECs
were treated by various concentrations of harmine for 48 hours.
(PPT)
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